ERBB2 and breast cancer: Another clinical trial, NCT05989347, is a single-arm Phase I study that examines whether dapagliflozin, administered in conjunction with standard neoadjuvant therapies, can favorably alter metabolic markers of insulin resistance in women with early-stage HER2- breast cancer.